Literature DB >> 18098298

Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force.

Bruno Dubois1, David Burn, Christopher Goetz, Dag Aarsland, Richard G Brown, Gerald A Broe, Dennis Dickson, Charles Duyckaerts, Jefferey Cummings, Serge Gauthier, Amos Korczyn, Andrew Lees, Richard Levy, Irene Litvan, Yoshikuni Mizuno, Ian G McKeith, C Warren Olanow, Werner Poewe, Cristina Sampaio, Eduardo Tolosa, Murat Emre.   

Abstract

A preceding article described the clinical features of Parkinson's disease dementia (PD-D) and proposed clinical diagnostic criteria for "probable" and "possible" PD-D. The main focus of this article is to operationalize the diagnosis of PD-D and to propose practical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment. Level I is aimed primarily at the clinician with no particular expertise in neuropsychological methods, but who requires a simple, pragmatic set of tests that are not excessively time-consuming. Level I can be used alone or in concert with Level II, which is more suitable when there is the need to specify the pattern and the severity on the dementia of PD-D for clinical monitoring, research studies or pharmacological trials. Level II tests can also be proposed when the diagnosis of PD-D remains uncertain or equivocal at the end of a Level I evaluation. Given the lack of evidence-based standards for some tests when applied in this clinical context, we have tried to make practical and unambiguous recommendations, based upon the available literature and the collective experience of the Task Force. We accept, however, that further validation of certain tests and modifications in the recommended cut off values will be required through future studies. 2007 Movement Disorder Society

Entities:  

Mesh:

Year:  2007        PMID: 18098298     DOI: 10.1002/mds.21844

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  307 in total

1.  The effect of CTAB, a cationic surfactant, on the absorption rate of [14C]tripalmitate from a test meal in the rat.

Authors:  B Isomaa; G Sjöblom
Journal:  Food Cosmet Toxicol       Date:  1975-10

2.  Neuropsychology, neuroimaging or motor phenotype in diagnosis of Parkinson's disease-dementia: which matters most?

Authors:  Francesca Di Biasio; Nicola Vanacore; Alfonso Fasano; Nicola Modugno; Barbara Gandolfi; Francesco Lena; Giovanni Grillea; Sara Pietracupa; Giovanni Caranci; Stefano Ruggieri
Journal:  J Neural Transm (Vienna)       Date:  2011-12-13       Impact factor: 3.575

3.  Episodic memory in dementia: Characteristics of new learning that differentiate Alzheimer's, Huntington's, and Parkinson's diseases.

Authors:  Eleni Aretouli; Jason Brandt
Journal:  Arch Clin Neuropsychol       Date:  2010-06-08       Impact factor: 2.813

Review 4.  Mild cognitive impairment in Parkinson's disease.

Authors:  J G Goldman; I Litvan
Journal:  Minerva Med       Date:  2011-12       Impact factor: 4.806

5.  Sentence processing in Lewy body spectrum disorder: the role of working memory.

Authors:  Rachel G Gross; Corey T McMillan; Keerthi Chandrasekaran; Michael Dreyfuss; Sharon Ash; Brian Avants; Philip Cook; Peachie Moore; David J Libon; Andrew Siderowf; Murray Grossman
Journal:  Brain Cogn       Date:  2012-01-02       Impact factor: 2.310

Review 6.  Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines.

Authors:  Irene Litvan; Jennifer G Goldman; Alexander I Tröster; Ben A Schmand; Daniel Weintraub; Ronald C Petersen; Brit Mollenhauer; Charles H Adler; Karen Marder; Caroline H Williams-Gray; Dag Aarsland; Jaime Kulisevsky; Maria C Rodriguez-Oroz; David J Burn; Roger A Barker; Murat Emre
Journal:  Mov Disord       Date:  2012-01-24       Impact factor: 10.338

7.  Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire.

Authors:  David Crosiers; Barbara Pickut; Jessie Theuns; Peter Paul De Deyn; Christine Van Broeckhoven; Pablo Martinez-Martin; K Ray Chaudhuri; Patrick Cras
Journal:  Am J Neurodegener Dis       Date:  2012-07-23

Review 8.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

9.  Distinct manifestation of cognitive deficits associate with different resting-state network disruptions in non-demented patients with Parkinson's disease.

Authors:  Kazuya Kawabata; Hirohisa Watanabe; Kazuhiro Hara; Epifanio Bagarinao; Noritaka Yoneyama; Aya Ogura; Kazunori Imai; Michihito Masuda; Takamasa Yokoi; Reiko Ohdake; Yasuhiro Tanaka; Takashi Tsuboi; Tomohiko Nakamura; Masaaki Hirayama; Mizuki Ito; Naoki Atsuta; Satoshi Maesawa; Shinji Naganawa; Masahisa Katsuno; Gen Sobue
Journal:  J Neurol       Date:  2018-02-01       Impact factor: 4.849

10.  Improvement of impulse control disorders associated with levodopa-carbidopa intestinal gel treatment in advanced Parkinson's disease.

Authors:  Maria Jose Catalan; Jose Antonio Molina-Arjona; Pablo Mir; Esther Cubo; Jose Matias Arbelo; Pablo Martinez-Martin
Journal:  J Neurol       Date:  2018-03-20       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.